Emerging Companies

As an exclusive members-only benefit, BIO offers complimentary One-on-One meeting rooms during the JP Morgan Healthcare Conference, taking place January 7-10, 2013, in San Francisco.

SBIR/STTR Reauthorization will restore eligibility to majority VC-backed emerging companies

For companies looking to partner in China, they must first realize the unique needs of this market.

Using an input output “I-O” approach to estimating the economic impact of academic licensing, and summing over the 15 years of available data for academic U.S. AUTM Survey respondents, the total contribution of these academic licensors to gross industry output ranges from $199B to $836B, in 2005 $US Dollars; contributions to GDP range from $86B to $338B, in 2005 $US Dollars.

BIO Ventures for Global Health (BVGH) and the Biotechnology Industry Organization (BIO) have collaborated on a new report that builds upon the findings in BVGH’s previous analysis, Developing New Drugs and Vaccines for Neglected Diseases of the Poor: The Product Developer Landscape.

Philip Vorhies, Practice Executive of Brand Management at Campbell Alliance, discusses the upcoming Product Delivery Workshop: Navigating the Path to Commercialization. The Workshop will be held June 18 & 19 during the 2012 BIO International Convention in Boston.

In this two part series, Scientific American’s Jeremy Abbate talks to editors Mike May and Yali Friedman about the Worldview Report and Scorecard, which will be released at the upcoming BIO International Convention in Boston at a Super Session on June 19.

In this two part series, Scientific American’s Jeremy Abbate talks to editors Mike May and Yali Friedman about the Worldview Report and Scorecard, which will be released at the upcoming BIO International Convention in Boston at a Super Session on June 19.

Phyllis discusses the importance of making connections in the industry to propel women into leadership roles, and plans for the upcoming BIO International Convention in Boston, Mass. On June 18-21.

Capital formation challenges in the industry have forced many biotech companies to halt projects, lay off staff or shutdown all together. Our analysis shows that the industry is approximately one-quarter smaller than it was in 2008.

BIO believes that the level of support provided by the TDP simply cannot meet the needs of the growing biotech field. As evidence of the project's popularity suggests, Congress should consider extending or expanding the project in order to support American innovation and speed the development of life-saving cures.

The biotech industry is a thriving sector employing 1.3 million Americans in high quality, high paying jobs.

Dr. Shawver discusses why this is an exciting time for the industry, and her experiences as a bench scientist turned CEO and founder of a patient advocacy group.

A new study shows that Kineret (anakinra), a medication approved for the treatment of rheumatoid arthritis, is effective in stopping the progression of organ damage in people with neonatal-onset multisystem inflammatory disease (NOMID).

Letters, Testimony & Comments

April 30 2015
On behalf of the Biotechnology Industry Organization Before the United States House of Representatives Committee on Financial Services, Subcommittee on Capital Markets and Government Sponsored Enterprises --- Legislative Proposals to Enhance Capital Formation and Reduce Regulatory Burdens
April 29 2014
Chairperson Mikulski, Ranking Member Shelby, Members of the Committee, thank you for the opportunity to provide you with written testimony on the extremely important topic of driving innovation through federal investments.
November 6 2013
On behalf of the BIO and its 1,100 members, I am writing in strong support of your Start-up Jobs and Innovation Act. I want to thank you for introducing this important legislation, which will spur investment in small biotech companies and other innovative businesses.
July 10 2013
A healthy public market is key to the success of the biotech industry, as growing innovators often turn to an IPO to fund late-stage clinical trials.
July 26 2012
Jeffrey S. Hatfield, President and Chief Executive Officer of Vitae Pharmaceuticals, testified on behalf of BIO about the 10th anniversary of the Sarbanes-Oxley Act.

Press Releases

August 11 2015
BIO Investor Forum to be held October 20-21 in San Francisco, California  
June 11 2015
BIO released a new report - Emerging Therapeutic Company Investment and Deal Trends – highlighting ten years (2005-2014) of biotechnology funding and deal making across five areas: venture capital, IPOs, follow-on public offerings, licensing, and acquisitions. The report also offers a first-time look at the degree of collaboration across the industry’s clinical pipeline.
May 21 2015
By making this tax credit permanent, companies conducting their development programs will be able to estimate their tax liability and will not be burdened by the constant uncertainty regarding whether or not the R&D Tax Credit will be extended.
May 13 2015
By teaming up with Aon, we are able to offer our members state-of-the-art coverage enhancements specific for life sciences companies...
May 7 2015
Program will improve liquidity and enhance capital formation for emerging biotech companies